Entero Therapeutics Total Liabilities

Entero Therapeutics's total liabilities stands at $20M as of March 2026. That compares with $29M in the prior-year period — down 28.8% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Entero Therapeutics reported $20M in total liabilities versus $29M a year earlier — a 28.8% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $29M in the prior-year period — down 28.8% year over year. Sustained growth in total liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Entero Therapeutics's total liabilities evolved across reporting periods, while the comparison chart places ENTO next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.